Agilent Technologies has entered into a development agreement with BioNanomatrix to develop a new genetic analysis system that combines technologies developed by both the companies. While financial details of the agreement were not disclosed, it is understood that BioNanomatrix will apply its single molecule imaging technology to develop consumable chips and reagents, while Agilent will develop the instrument platform for the system. "BioNanomatrix's unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life sciences research and clinical medicine," said Nick Roelofs, vice president and general manager of the Life Sciences Solutions Unit at Agilent. According to Dr Michael Boyce-Jacino, CEO of BioNanomatrix these applications include "assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing." Bruker Biospin has launched a new range of fee for analytical services programme that will give customers direct access to the latest Bruker technologies for NMR (nuclear magnetic resonance) FTIR (fourier transform infrared) and Raman spectroscopy. The programme is designed to assure the highest quality service while enabling customers to minimise their infrastructure costs at their laboratory sites. "Early service opportunities highlight our strengths in NMR, TD-NMR, and FTIR applications," said Paul Dawson, sales manager for the new Bruker Analytical Services Division. "With demand coming from such widespread markets as Pharmaceutical, Biotech, Petroleum industry and Academia, we are expanding our capabilities every day with resources from the entire Bruker family of technologies." Dolomite, the "World's first microfluidic application centre" has expanded its presence in India with the appointment of Niulab Equipment as its Indian distributor of microfluidic services and capabilities. "This appointment reflects the increasing level of interest we are experiencing around the world from customers interested in working with us to bring their microfluidic concepts to market," said Gillian Davis, commercial director of Dolomite. "Appointing a technical company as experienced and capable as Niulab Equipment will be instrumental in helping to secure business and manage customer relations in this territory." Oxford Gene Technology (OGT) has licensed its "Southern array patents" to Taiwan's Phalanx Biotech Group, enabling Phalanx to fabricate and sell arrays, including its OneArray for gene expression profile studies in the US. The patents, developed in Professor Sir Edwin Southern's laboratories at the University of Oxford, cover the manufacture and marketing of oligonucleotide arrays and can be used to determine the number of copies of genes in a genome. The northern blot is a similar procedure used for determining gene expression by RNA and derives its name from a pun on Prof. Southern's name, while the western blot is used to detect proteins. "This is a significant deal as it is the first licence granted to a Taiwanese company and reflects OGT's continuing portfolio expansion in Asia," said Dr Michael Bennett, vice president for Licensing and Patents at OGT. Roche Applied Science has licensed its melting curve analysis technique to Eppendorf for an undisclosed amount. The technique enables the analysis of PCR (polymerase chain reaction) products by determining the melting temperature (Tm), defined as the temperature at which 50 per cent of the double stranded DNA becomes single stranded. This new deal builds upon the protein expression cooperation agreement signed by the two companies in July. "We regard the licensing of the melting curve analysis technique as an important contribution to further developing this technology in the life science field," said Manfred Baier, Head of Roche Diagnostics' Applied Science division.